This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

GenVec Value Slammed on Drug Failure

(Updated with Tuesday's closing GenVec stock price.)

GAITHERSBURG, Md. ( TheStreet) -- GenVec's (GNVC - Get Report) experimental pancreatic cancer drug TNFerade is no better than a placebo, forcing the shut down a pivotal late-stage study, the company said Monday night.

The failure of the GenVec drug TNFerade after a second interim analysis of the phase III study is a huge setback for the company. GenVec shares closed 71.5% at 80 cents Tuesday.

By my quick calculations, GenVec has roughly 26 cents a share in cash. Throw in a few pennies for the rest of the company's drug pipeline, minus TNFerade, and fair value Tuesday morning should be around 30 cents a share.

TNFerade's blowup is not altogether surprising given the less-than-comforting data from the first look at the same study in November 2008.

GenVec's stock price dipped below 40 cents a share at that time, with an assist from the global financial crisis. Yet the stock fully recovered and even breached $3 a share this month, which tells you investors were betting on a come-from-behind victory a la Human Genome Sciences (HGSI). Sadly, what investors are getting is a Medivation (MDVN - Get Report)-style schmeissing.

Pancreatic cancer patients treated with TNFerade combined with radiation and chemotherapy had an 8% reduction in the risk of death compared to treatment with radiation and chemotherapy alone, according to the second interim analysis of the 330-patient phase III study released Monday night.

That corresponds to a hazard of 0.92, just slightly in favor of TNFerade. Simply defined, the hazard ratio is an estimate of the treatment effect of TNFerade plus the standard of care compared to the treatment effect of the standard of care alone.

For perspective, two treatments are equally effective when the hazard ratio of a study hits 1. Unfortunately, TNFerade was getting much closer to placebo over time -- which explains why GenVec was forced to halt the study.

TNFerade efficacy dwindled over time. When GenVec performed the first interim analysis of the phase III study in November 2008, the hazard ratio in favor of TNFerade was 0.75, which meant TNFerade patients had a 25 percent reduction in the risk of death.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs